Jasmine was 26, twenty-four weeks pregnant, and trying to do the right thing. She had been using heroin for three years before learning she was pregnant, and after her first prenatal visit at a clinic in Memphis, Tennessee, she decided she was going to quit. Cold turkey. By herself. Forty hours into withdrawal she was vomiting, sweating, cramping, and frightened. Her boyfriend drove her to the emergency room. The triage nurse did her vitals, looked at her belly, and immediately paged the obstetrician on call. The obstetrician was direct with Jasmine in a way she did not expect. “Stopping suddenly is more dangerous for the baby than continuing,” she said. “We are going to start you on buprenorphine here tonight, with monitoring. We are not detoxing you off opioids during pregnancy. The evidence does not support it. The plan is medication-assisted treatment, prenatal care, and a delivery plan.” Jasmine cried — partly from the relief of being treated as a patient instead of a problem, partly from the fear of what the baby was facing. The hospital team admitted her, started buprenorphine induction, and arranged outpatient follow-up at a clinic that accepted pregnant patients. She delivered a healthy boy at 38 weeks. He spent eight days in the NICU for neonatal abstinence syndrome and came home with her.
A pregnancy detox program is rarely what most people imagine. Decades of research have made clear that, for opioid use disorder in particular, abrupt withdrawal during pregnancy is dangerous to both mother and fetus, and the standard of care is not detoxification but stabilisation on medications such as methadone or buprenorphine. For alcohol, benzodiazepines, and some other substances, medical detoxification during pregnancy is sometimes appropriate but always inpatient, always supervised, and always coordinated with obstetric care. Understanding why home detox or sudden cessation is dangerous, and what actually constitutes safe care, is critical for any pregnant person and family confronting substance use during pregnancy.
Why home or sudden detox is dangerous in pregnancy
Maternal stress hormones cross the placenta. When a pregnant person enters acute opioid withdrawal, the surge in cortisol, adrenaline, and noradrenaline produces a fetal stress response. The fetus may experience tachycardia, decreased oxygen delivery, and in severe cases, intrauterine demise. Maternal vomiting and diarrhea cause dehydration and electrolyte disturbance, further compromising placental perfusion. Withdrawal-driven cravings often lead to relapse, and the relapse — using street opioids of unknown potency, often contaminated with fentanyl — carries a high overdose risk that endangers mother and fetus simultaneously.
The American College of Obstetricians and Gynecologists (ACOG), the American Society of Addiction Medicine, the World Health Organization, and the Substance Abuse and Mental Health Services Administration all explicitly recommend medication-assisted treatment with methadone or buprenorphine, not detoxification, as the standard of care for opioid use disorder in pregnancy. The phrase often used in the literature is “detox-and-quit is not an evidence-based pathway for opioid use disorder during pregnancy.”
The MOTHER trial: methadone vs buprenorphine
The Maternal Opioid Treatment: Human Experimental Research (MOTHER) trial, published in the New England Journal of Medicine in 2010, was a randomised controlled trial comparing methadone and buprenorphine maintenance in pregnant women with opioid use disorder. The trial found both medications safe and effective for the mother. Babies exposed to buprenorphine in utero had shorter hospital stays, less morphine treatment for neonatal abstinence syndrome, and lower peak NAS scores compared with methadone-exposed babies. Both groups had similar rates of birth weight, gestational age at delivery, and other obstetric outcomes.
Since MOTHER, buprenorphine has gained ground as a first-line option in many programs, particularly for women without high-dose long-term methadone needs. Methadone remains appropriate for many patients, particularly those already stabilised on it before pregnancy or those with very heavy use histories. The choice is individualised, made by an addiction-trained obstetrician or perinatal addiction medicine specialist. Our coverage of substance use during pregnancy walks through these decisions in more detail.
Alcohol detox in pregnancy
Alcohol is different from opioids in several critical ways during pregnancy. Continued alcohol exposure in utero causes fetal alcohol spectrum disorders, with permanent neurodevelopmental consequences. Unlike opioids, where the goal is stable maintenance, the goal with alcohol is full cessation. But abrupt withdrawal in a pregnant woman with significant alcohol use disorder carries the same medical risks as in non-pregnant patients (seizures, delirium tremens, death) plus pregnancy-specific risks of preterm labor and fetal distress.
The standard for alcohol detoxification during pregnancy is medical inpatient admission with continuous fetal monitoring, intravenous fluids, thiamine supplementation (Wernicke’s encephalopathy prevention is especially important in malnourished pregnant women), and benzodiazepines used cautiously per the obstetric team’s risk assessment. Lorazepam is sometimes preferred over longer-acting benzodiazepines to minimise fetal accumulation. The protocol is closer to a medical hospitalization than to a typical detox center stay. Outpatient alcohol detox is generally not appropriate during pregnancy.
Benzodiazepine taper considerations
Benzodiazepine use in pregnancy is complicated. Long-term use is associated with possible neonatal withdrawal symptoms, neonatal sedation, and possibly small increases in certain birth defects, though the evidence is mixed. Sudden cessation produces seizure risk for the mother and stress on the fetus. The general approach for long-term benzodiazepine users in pregnancy is a slow taper coordinated between the obstetrician, addiction medicine, and psychiatry, often over weeks rather than days, with the recognition that some patients will require continued low-dose maintenance until after delivery.
Benzodiazepine tapers in pregnancy are typically not done in standard detox centers because the timeline is incompatible with detox-center models. They are managed through outpatient addiction-pregnancy programs or, when stabilisation is needed, through inpatient medical or maternal-fetal medicine admissions.
Finding pregnancy-accepting detox via the SAMHSA locator
The Substance Abuse and Mental Health Services Administration operates a free, confidential treatment locator at the SAMHSA website. The locator allows users to filter for facilities that accept pregnant women, offer specialised programs for pregnant or postpartum women, and provide medication-assisted treatment. SAMHSA’s helpline (1-800-662-HELP) is staffed 24 hours a day. State Medicaid programs typically cover pregnancy-related substance use treatment, and most states have specific maternal addiction medicine programs at academic medical centers.
The Office on Women’s Health, part of the US Department of Health and Human Services, provides additional consumer-facing information through its Women’s Health website, including resources specific to pregnancy and substance use. For broader pregnancy-related mental health crisis information, see our piece on postpartum and pregnancy-related crisis presentations.
Lessons from Tennessee’s fetal assault law repeal
From 2014 to 2016, Tennessee was the only US state with a fetal assault law that allowed criminal prosecution of women whose newborns showed evidence of in utero substance exposure. The law was passed with the stated intent of pushing women into treatment but produced the opposite effect in practice. Pregnant women avoided prenatal care for fear of testing and prosecution. They delivered outside hospitals. They lied to medical providers. Treatment programs reported declining referrals from the affected population. The legislature allowed the law to sunset in 2016 after public health authorities, addiction medicine specialists, obstetricians, and child welfare experts documented the harms.
The lesson, repeatedly emphasised by ACOG and the American Academy of Pediatrics, is that punitive approaches to substance use during pregnancy worsen outcomes for mothers and babies. Treatment, not prosecution, produces healthier deliveries. Medical confidentiality, voluntary engagement, and access to medication-assisted treatment are the policy levers that produce healthy births. Some states still have child welfare reporting requirements triggered by positive newborn toxicology screens, and pregnant patients should ask treatment programs and obstetric providers about reporting policies in their specific state.
Postpartum continuation
The postpartum period is one of the highest-risk windows for relapse and for maternal mortality from overdose. Sleep deprivation, hormonal shifts, the stress of newborn care, and the abrupt change from intensive prenatal monitoring to lighter postpartum follow-up combine to destabilise recovery. Effective postpartum continuation includes maintenance of methadone or buprenorphine (often with dose adjustment after delivery), continued behavioral treatment, peer support, postpartum depression screening, contraception counseling for any future pregnancy planning, and active linkage to community-based addiction medicine.
Programs that follow mothers from prenatal through postpartum (often called “wraparound” or “perinatal addiction” programs) produce the best outcomes. They typically include mother-baby visits, lactation support compatible with MAT (both methadone and buprenorphine are compatible with breastfeeding for most patients), and concurrent treatment of co-occurring depression, anxiety, or trauma. Our piece on postpartum continuity of care covers this transition in greater depth.
What to expect from a maternal addiction medicine program
A typical maternal addiction medicine program integrates: obstetric care delivered by clinicians experienced with pregnancy-substance use overlap; medication-assisted treatment (methadone via licensed opioid treatment programs, or buprenorphine via DATA-waivered providers, with the X-waiver requirement removed in 2023); behavioral health (individual therapy, group therapy, often with trauma-informed approaches given high rates of trauma history in this population); social work and case management for housing, child welfare, transportation, and benefits; and pediatric coordination for the planned NAS management at delivery.
Programs of this type exist at most academic medical centers and many federally qualified health centers in the US. State Medicaid often covers care extensively for pregnant women with substance use disorder, including in states that have not expanded Medicaid for the general adult population.
Frequently asked questions
Will my baby be born with withdrawal symptoms?
Babies exposed to opioids in utero — whether to methadone, buprenorphine, or street opioids — may develop neonatal abstinence syndrome (NAS), now often called neonatal opioid withdrawal syndrome. NAS is a treatable condition managed in the NICU with non-pharmacologic care (rooming-in with mother, swaddling, low stimulation) and, when needed, morphine or buprenorphine for the baby. Outcomes are generally very good with appropriate management.
Can I breastfeed if I am on methadone or buprenorphine?
For most women on stable doses of methadone or buprenorphine without other contraindications (HIV, active polysubstance use, certain other conditions), breastfeeding is recommended. Both medications cross into breast milk in only minimal amounts and breastfeeding may help reduce NAS severity. Discuss specifics with your obstetrician and pediatrician.
Will child welfare take my baby if I am on MAT?
This depends on state law and practice. Being on prescribed methadone or buprenorphine is not, by itself, child neglect; it is medical treatment of a chronic condition. Some states have specific protections for women in MAT. Engaging openly with prenatal care, demonstrating treatment adherence, and having a postpartum plan are protective. A social worker at your treatment program can clarify state-specific reporting policies.
What if I want to detox completely off opioids before delivery?
This is generally not recommended. The evidence shows higher relapse rates after pregnancy-period detoxification compared with continued maintenance, and relapse during pregnancy carries serious risks. Some women have successfully tapered under careful supervision in specialised settings, but it is not the standard recommendation and should only be considered with a maternal addiction medicine specialist’s input.
Does insurance cover pregnancy MAT?
Yes, generally. Medicaid in particular covers MAT in pregnancy in all states, often with no copay. Private insurance is required by federal parity law to cover substance use treatment on equal terms with medical care. Coverage of methadone specifically may require enrollment in a licensed opioid treatment program; buprenorphine is dispensed through ordinary pharmacies.
The bottom line
The intuitive idea that quitting opioids cold turkey during pregnancy is “doing the right thing” is, by every major medical society’s evidence-based guidance, exactly wrong. Pregnancy is not the time to detox off opioids. It is the time to enter medication-assisted treatment, prenatal care, and a coordinated delivery plan. For alcohol and benzodiazepines, medical inpatient detoxification in coordination with obstetric care is the appropriate approach when needed. Punitive policies, hidden use, and home detox attempts harm mothers and babies; integrated, treatment-focused, confidential maternal addiction care produces healthy deliveries. Jasmine, the patient from Memphis, is two years postpartum, still on buprenorphine, working part-time, and parenting a healthy toddler. The path that started in an emergency room with a clinician who told her the truth is the path that brought her here.
If you are in crisis
If you are pregnant and in crisis or experiencing withdrawal, call 988 for mental health crisis support, 911 for medical emergencies, or SAMHSA’s helpline at 1-800-662-HELP (4357) for 24-hour treatment referral. Do not attempt unsupervised opioid, alcohol, or benzodiazepine withdrawal during pregnancy.
This article is for educational purposes only and is not medical advice. Always consult an obstetrician and addiction medicine clinician for guidance specific to your pregnancy and treatment.